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Abstract
Background: Cancer progression is linked to a partially dedifferentiated epithelial cell phenotype.
The signaling pathways Wnt, Hedgehog, TGF-β and Notch have been implicated in experimental
and developmental epithelial mesenchymal transition (EMT). Recent findings from our laboratory
confirm that active Wnt/β-catenin signaling is critically involved in invasive ductal carcinomas
(IDCs) of breast.
Methods: In the current study, we analyzed the expression patterns and relationships between
the key Wnt/β-catenin signaling components- E-cadherin, Slug and GSK3β in IDCs of breast.
Results: Of the 98 IDCs analyzed, 53 (54%) showed loss/or reduced membranous staining of E-
cadherin in tumor cells. Nuclear accumulation of Slug was observed in 33 (34%) IDCs examined.
Loss or reduced level of cytoplasmic GSK3β expression was observed in 52/98 (53%) cases; while
34/98 (35%) tumors showed nuclear accumulation of GSK3β. Statistical analysis revealed
associations of nuclear Slug expression with loss of membranous E-cadherin (p = 0.001); nuclear β-
catenin (p = 0.001), and cytoplasmic β-catenin (p = 0.005), suggesting Slug mediated E-cadherin
suppression via the activation of Wnt/β-catenin signaling pathway in IDCs. Our study also
demonstrated significant correlation between GSK3β nuclear localization and tumor grade (p =
0.02), suggesting its association with tumor progression.
Conclusion: The present study for the first time provided the clinical evidence in support of Wnt/
β-catenin signaling upregulation in IDCs and key components of this pathway - E-cadherin, Slug and
GSK3β with β-catenin in implementing EMT in these cells.
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Background
Breast cancer is a major cause of female mortality in the
Western world. In India, it is the second most common
cancer among females, while in the metropolitan cities; it
ranks as the most common cancer [1]. The incidence rate
is low as compared to the west with an age-adjusted inci-
dence of 19.1 per 100,000 women and a crude incidence
of 16.5 per 100,000 women [2]. The key biological proc-
esses such as embryonic development, tissue remodeling,
restitution and wound repair, require epithelial cells to
escape from the rigid structural constraints of the tissue
architecture and adopt a phenotype more amenable to
cell migration and movement. The highly conserved and
fundamental process that achieves this morphogenetic
transformation is known as epithelial-mesenchymal tran-
sition (EMT) [3,4]. The progression of tumors to invasive
cancers and metastatic disease also involves localized
occurrence of EMT [5,6].
Loss of E-cadherin mediated cell adhesion is one of the
key mechanisms involved in metastatic conversion of epi-
thelial cells and EMT [7,8]. Numerous studies have
described a partial or complete loss of E-cadherin during
cancer progression [9-12], which is often correlated with
an unfavorable prognosis [13,14], confirming E-cadherin
to be a caretaker of the epithelial state. One of the proba-
ble mechanisms involved in E-cadherin dysfunction,
especially loss of its expression and consequent promo-
tion of tumor progression is through β-catenin signaling.
Several other mechanisms of E-cadherin downregulation
have been described. Mutations have been found in the
CDH1 gene in about 50% of lobular carcinomas of the
breast [15], while ductal breast cancers show heterogene-
ous loss of E-cadherin expression, associated with epige-
netic transcriptional downregulation. Analysis of CDH1
methylation in breast cancers and other tumor types has
shown that aberrant hypermethylation of CpG islands in
CDH1 promoter region often occurs prior to invasion,
indicating it to be an early event in tumorigenesis [16].
Besides regulation of CDH1  by promoter methylation
and/or genetic alterations, direct transcriptional control of
CDH1 has emerged as an important regulatory mecha-
nism of E-cadherin expression. The proteins Snail, Slug,
and Twist have been recently characterized as transcrip-
tional repressors of E-cadherin in breast carcinoma and
are regulated by Wnt/β-catenin signaling [17,18]. Slug
expression has been shown to correlate more strongly
than snail expression with loss of E-cadherin in breast
cancer cell lines, suggesting Slug to be a likely in vivo
repressor of E-cadherin expression in breast carcinoma
[19].
The key components of EMT and Wnt pathways are sche-
matically depicted in Figure 1. Recent results obtained in
our laboratory showed that canonical Wnt signaling is
one of the signaling pathways possibly involved in the
control of the migration/invasive behavior of Invasive
ductal carcinoma of breast (IDCs) [20,21]. We demon-
strated the disorganization of E-cadherin-β-catenin com-
plexes and the regulation of vimentin expression by β-
catenin mediated pathway in IDCs, thereby supporting
the notion that Wnt/β-catenin signaling is implicated in
regulation of EMT [21].
E-cadherin, Slug and Glycogen synthase kinase 3β
(GSK3β) play important roles in EMT transition via Wnt/
β-catenin signaling. GSK3β resides at the junction of
PI3K/AKT and Wnt/β-catenin/TCF survival pathways,
thereby serving critical roles in cellular metabolism,
growth and proliferation [22,23]. Under un-stimulated
conditions, GSK3β pools are constitutively active, but
they are phospho-inhibited upon PI3K/AKT or Wnt acti-
vation [24], resulting in cytoplasmic and nuclear accumu-
lation of β-catenin.
Recent studies from our laboratory as well as by others
substantiate the role of active Wnt/β-catenin pathway in
proliferation and induction of EMT in tumor cells
[5,20,21]. Taking our previous findings into considera-
tion, the primary aim of this study was to determine the
expression patterns of integral components of the canon-
ical Wnt/β-catenin signaling- GSK3β, E-cadherin and Slug
in IDCs and their associations with clinicopathological
parameters for better understanding the biological and
clinical relevance of Wnt/β-catenin pathway activation in
sporadic breast cancer.
Methods
Tissue Specimens
Surgically resected specimens from untreated primary
breast carcinomas and paired normal breast tissues were
collected from 98 breast cancer patients enrolled in the
Out Patients Department of Surgical Disciplines, Safdar-
jung Hospital and All India Institute of Medical Sciences
(New Delhi, India), after approval of the study by Institu-
tional Human Ethics Committee. Written consent was
taken from all the patients enrolled in the study. The age
of the patients ranged from 30-81 years with median age
of 56 years. All the patients included in this study were
invasive ductal breast carcinoma patients and their clin-
icopathological parameters are summarized in Table 1. In
addition, 5 cases of Invasive lobular carcinomas (ILCs)
were included to compare the expression of these proteins
in ILCs and IDCs.
Immunohistochemical analysis of E-cadherin, Slug and 
GSK3β
Immunohistochemical analysis of E-cadherin, Slug and
GSK3β was carried out using paraffin embedded tissue
sections as described by us previously [20,21]. E-cadherinBMC Cancer 2009, 9:325 http://www.biomedcentral.com/1471-2407/9/325
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Schematic diagram showing Wnt/β-catenin signaling in Invasive ductal carcinomas of breast Figure 1
Schematic diagram showing Wnt/β-catenin signaling in Invasive ductal carcinomas of breast: On activation of 
Wnt signaling, disheveled (Dvl) prevents degradation of β-catenin, possibly through the recruitment of GBP/Frat-1, which in 
turn displaces GSK3β from the destruction complex. Adenomatous Polyposis Coli (APC), an important component of Wnt 
signaling was also found to downregulated by promoter methylation, as one of the mechanism [21]. Stabilized β-catenin enters 
the nucleus and associates with T cell factor (TCF)/lymphoid enhancer factor (LEF) transcription factors, which leads to the 
transcription of Wnt target genes such as cyclin D1, vimentin and slug [20,21]. Mechanisms attributed in the downregulation of 
E-cadherin are DNA methylation/or by transcriptional suppression via snail/or slug, thereby releasing membrane bound β-cat-
enin into the cytosol [21].
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monoclonal antibody (sc-8426) and Slug polyclonal anti-
body (sc-15391) were purchased from Santa Cruz Bio-
technology Inc. (Santa Cruz, CA). Monoclonal GSK3β
antibody (Cat. No.610201) was procured from BD Bio-
sciences (San Jose, CA). The monoclonal antibodies were
used at 1:100 dilution and the polyclonal antibody was
used at 1:50 dilution. In the negative controls, the primary
antibody was replaced by isotype- specific IgG.
Scoring Criteria for Immunohistochemical Staining
Evaluation of immunohistochemistry was carried out by
two investigators independently (CPP, SM). Tumors were
classified based on the percentage of cells showing immu-
noreactivity. The immunostained slides were scored as per
the following criteria for all the three proteins: no detect-
able staining, negative; +, ≤ 10%; ++, 10-50%; +++, >50%
of positive tumor cells. Tumors were regarded as immuno-
positive if >10% of tumor cells showed immunoreactivity.
For the transcription factor Slug, detectable immunoreac-
tivity in nuclear region was defined as positive expression
[18]. Expression of E-cadherin protein was localized in
membrane/cytoplasm/or both in IDCs, both membra-
nous and cytoplasmic expression were considered as event
[25]. Nuclear/cytoplasmic staining was considered posi-
tive for GSK3β [26].
Immunoblot analysis of E-cadherin, GSK3β and Slug in 
breast normal tissues and IDCs
Tissue lysates were prepared from 4 normal breast tissues
(collected from 5-7 cm away of tumor periphery from rad-
ical mastectomy specimen) and 4 IDCs. Frozen tissue
samples were homogenized and lysed in RIPA buffer con-
taining 1× protease inhibitor cocktail. Protein concentra-
tions were determined using the Bradford assay (Sigma
Chemicals, Bangalore, India) and equal amounts of pro-
teins (80 μg/lane) from tissue lysates were electro-
phoresed in 10% sodium dodecyl sulfate-polyacrylamide
gels and then transferred onto Polyvinylidenedifluoride
Table 1: Relationships between expression of E-cadherin, Slug and GSK3β in IDCs of breast: Correlation with clinicopathological 
parameters
Parameter Total Cases (N) E-Cad (Mem) E-Cad (Cyto) Slug (Nucl) Gsk3β (Nucl) Gsk3β (Cyto)
- + P -+ P -+ P -+ P -+ P
98 53 45 46 52 65 33 64 34 52 46
Age
 50 62 30 32 .148 24 38 0.06 40 22 .663 44 18 0.131 30 32 .294
> 5 0 3 6 2 3 1 3 2 21 4 2 51 1 2 01 6 2 21 4
Menopausal status
Pre- 35 19 16 1.00 12 23 0.091 22 13 .658 27 8 .079 19 16 1.00
P o s t - 6 3 3 4 2 9 3 42 9 4 32 0 3 72 6 3 33 0
Tumor grade
T1+T2 53 24 29 .060 21 32 0.155 29 24 .01*1 29 24 .02*2 26 27 .422
T3+T4 45 29 16 25 20 36 9 35 10 26 19
Lymphatic involvement
N0 36 19 17 1.00 18 18 0.679 22 14 .507 20 16 0.131 18 18 .675
N1-2 62 34 28 28 34 43 19 44 18 34 28
Grade
I+II 56 27 29 .221 22 34 0.103 33 23 .087 32 24 .05*3 31 25 .684
III+IV 42 26 16 24 18 32 10 32 10 21 21
ER
+ v e 2 8 1 7 1 1 . 5 0 2 1 31 51 . 0 0 1 51 3. 1 0 3 1 31 5. 0 1 9 * 4 17 11 .377
- v e 7 0 3 6 3 4 3 33 7 5 02 0 5 11 9 3 53 5
*TNM Classification on basis of AJCC classification [46]. Abbreviations: E-cad, E-cadherin; Cyto, Cytoplasmic; Nucl, Nuclear and Mem, 
Membrane. *1p = 0.01; OR = 0.191 [95% CI = 0.122-0.75]; *2p = 0.02; OR = 0.3 [95%CI = 0.142-0.838]; *3p = 0.05; OR = 0.417 [95%CI 
= 0.172-1.01]; *4p = 0.019; OR = 3.09 [95%CI= 1.24-7.09]. * p values were calculated using Fischer exact test. p < 0.05 was considered as 
significant and are given in the table. Analysis of relationships between E-cadherin, Slug and GSK3β expression in IDCs showed the following 
significant associations: E-cad (Mem)-/Slug (Nucl)+: p = 0.001; OR = 4.49 [95% C.I = 1.82-11.8]; E-cad (Cyto)+/E-cad (Mem)-: p = 0.016; 
OR = 2.82 [95% C.I = 1.23-6.44]; E-cad (Cyto)+/Slug (Nucl)+: p = 0.031; OR = 2.88 [95% C.I = 1.17-6.95]; GSK3β (Cyto)+/GSK3β 
(Nucl)+: p = 0.012; OR = 3.06 [95% CI = 1.28-7.27].BMC Cancer 2009, 9:325 http://www.biomedcentral.com/1471-2407/9/325
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(PVDF) membranes. After blotting in 5% non-fat dry milk
in Tris-buffered saline, blots were incubated with anti-E-
cadherin antibody (1:500 dilution), anti-GSK3β antibody
(1:1000 dilution), and anti-Slug antibody (1:200 dilu-
tion) at 4°C overnight. Membranes were incubated with
secondary antibody, HRP-conjugated rabbit/mouse anti-
IgG (DAKO Cytomation, Denmark), diluted at an appro-
priate dilution in 1% BSA, for 2 hrs at room temperature.
Protein bands were visualized on X-ray film using an
enhanced chemiluminescence system (ECL, Santa Cruz
Biotechnology, CA).
Statistical Analysis
All the statistical analysis were performed using SPSS 10.0
for Windows. (SPSS Inc., Chicago, IL). Chi-Square test
and Fischer's exact test (2-sided) were performed for deter-
mining the correlation between clinicopathological
parameters and protein expression. Results were consid-
ered significant when p value was < 0.05.
Results
Immunohistochemical analysis of E-cadherin, GSK3β and 
Slug in Invasive ductal carcinoma of breast
The results of immunohistochemical analysis of E-cad-
herin, GSK3β and Slug expression in IDCs are summa-
rized in Table 1. Strong membranous E-cadherin
immunostaining was observed in normal breast tissues
(Figure 2A). Of the 98 IDCs examined, 53/98 (54%)
showed loss/or reduced membranous staining of E-cad-
herin in tumor cells; 52/98 (53%) of IDCs showed cyto-
plasmic accumulation of the protein (Figure 2B). No
association was found between loss of membranous/or
cytoplasmic accumulation of E-cadherin expression with
any of the clinicopathological parameters (Table 1).
Slug was expressed in 33 of 98 (34%) IDCs examined
(Table 1), while the paired histological normal breast tis-
sues did not show detectable levels of Slug protein (Figure
2C). Expression of Slug protein was observed in cyto-
plasm/nucleus/or both, however, only nuclear expression
was considered as immunopositive for Slug (Figure 2D).
Significant inverse association was observed between
nuclear accumulation of Slug and tumor stage [p = 0.01;
OR = 0.191; (95% CI = 0.122-0.75)] in IDCs (Table 1).
GSK3β expression was localized in the cytoplasm/or
nucleus of epithelial cells in normal breast tissues (Figure
2E). In comparison loss/or reduced level of cytoplasmic
GSK3β expression was observed in 52/98 (53%) breast
carcinomas, while 34/98 (35%) of IDCs showed nuclear
accumulation of GSK3β (Figures 1F &1G respectively).
Nuclear GSK3β was inversely associated with tumor stage
[p = 0.02; OR = 0.3; (95% CI = 0.142-0.838)] and histo-
logical grading [p = 0.05; OR = 0.417 (95% C.I = 0.172-
1.01)] in IDCs (Table 1). Positive association was also
observed between GSK3β nuclear expression and ERα
receptor positivity [p = 0.019; OR = 3.09; (95% CI = 1.24-
7.09)]. Furthermore, immunohistochemical confirmed
cases of IDCs and normal breast tissues were revalidated
by Western blotting for protein expression. Western Blot
analysis independently confirmed the immunohisto-
chemical findings of E-cadherin, GSK3β and Slug proteins
expressions in IDCs of breast and paired normal breast tis-
sues (data not shown).
Expression patterns of E-cadherin, GSK3β and Slug in 
Invasive lobular carcinomas (ILCs) of breast
Five sections of histological confirmed Invasive lobular
carcinoma (ILC) of breast were also analyzed for E-cad-
herin, Slug and GSK3β staining. Four of 5 ILCs showed
complete loss of E-cadherin protein, as shown in Figure
2A and 2B. Distinct slug nuclear localization was observed
in 3 of the 5 ILCs analyzed (Figure 2C); whereas, all the 5
ILCs showed no detectable expression of GSK3β protein
(Figure 2D).
Relationship between E-cadherin, GSK3β and Slug 
expression in IDCs
Significant association was observed between nuclear
expression of Slug and loss of membranous E-cadherin [p
= 0.001; OR = 4.49 (95% C.I = 1.82-11.8)]. Figure 2H and
2I show nuclear accumulation of Slug and loss of E-cad-
herin immunostaining respectively examined on consecu-
tive sections of the same tumor in representative cases,
supporting the association between these proteins found
by statistical analysis. Positive associations were also
observed between cytoplasmic accumulation E-cadherin
protein and loss of membranous E-cadherin [p = 0.016;
OR = 2.82 (95% C.I = 1.23-6.44)] as well as with nuclear
Slug [p = 0.031; OR = 2.88 (95% C.I = 1.17-6.95)]. Posi-
tive association was also observed between cytoplasmic
and nuclear accumulation of GSK3β [p = 0.012; OR = 3.06
(95% C.I = 1.28-7.27)] (Table 1).
Association of β-catenin with E-cadherin, Slug and GSK3β 
in IDCs
The expression and sub-cellular distribution of β-catenin
in these IDCs has been reported by us earlier in the same
cohort [20]. Here in statistical analysis showed significant
associations between β-catenin expression and E-cad-
herin, Slug and GSK3β, as summarized in Table 2. Loss of
membranous E-cadherin was significantly associated with
loss of membranous β-catenin [p = 0.0001; OR = 5.59
(95% C.I = 2.21-14.10)]. Positive association was
observed between cytoplasmic localization of E-cadherin
and nuclear β-catenin [p = 0.046; OR = 2.33 (95% CI =
1.03-5.25)]. Nuclear accumulation of Slug showed signif-
icant association with nuclear β-catenin [p = 0.001; OR =
4.87 (95% C.I = 1.94-12.21)]; cytoplasmic β-catenin accu-
mulation [p = 0.005; OR = 3.67 (95% C.I = 1.53-8.83)]BMC Cancer 2009, 9:325 http://www.biomedcentral.com/1471-2407/9/325
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and β-catenin membranous loss [p = 0.012; OR = 3.25
(95% C.I = 1.34-7.89)].
Of the 98 IDCs analyzed, 33 tumors showed nuclear accu-
mulation of Slug. Of these 33 tumors, 17 (51%) IDCs
showed nuclear localization of β-catenin protein (p
0.01); while 23 (70%) cases showed loss of membranous
E-cadherin expression (p  0.01). Twelve of 33 (36%) IDCs
showed both nuclear localization of β-catenin protein
and loss of membranous E-cadherin.
Discussion
Recent studies demonstrate that canonical Wnt signaling
pathway is associated with both stem cell and tumor cell
development [27-29]. In many tissues, where stem cell
attributes are under the control of Wnt pathway, aberrant
activation of this pathway results in tumor formation
[30]. Our current findings support the accumulating evi-
dence that hyperactive Wnt signaling is associated with
development and progression of human breast cancer
[20,21,31]. Herein, we provide clinical evidence to dem-
onstrate that alterations in expression of the key compo-
nents of Wnt/β-catenin pathway- E-cadherin, GSK3β and
Slug occur in the pathogenesis of IDCs.
During EMT, the epithelial cells acquire fibroblast-like
properties and show reduced intercellular adhesion and
increased motility; this process is associated with func-
tional loss of E-cadherin [32,33]. Further, down regula-
tion of E-cadherin is the key step towards invasive phase
of cancer progression; promoter methylation/transcrip-
tional repression are mechanisms largely responsible for
Expression of E-cadherin, Slug and GSK3β proteins in invasive ductal carcinomas of breast Figure 2
Expression of E-cadherin, Slug and GSK3β proteins in invasive ductal carcinomas of breast. (A) Strong membra-
nous E-cadherin expression in normal breast tissue (B) Loss of E-cadherin membranous localization in tumor cells. (C) Loss of 
Slug protein in normal breast (D) Nuclear accumulation of Slug in IDC (E) GSK3β expression in normal breast epithelium (F) 
IDC showing loss cytoplasmic GSK3β (G) GSK3β nuclear localization in tumor cells; and (H&I) Nuclear accumulation of Slug 
and loss of E-cadherin immunostaining examined on the adjacent sections of the same tumor. (A-I, original magnification × 
400). Arrows show Membranous (M), Nuclear (N) and cytoplasmic (C) localization of the proteins.
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loss of E-cadherin expression in IDCs [34-36]. Recent data
from our laboratory suggests that absence of E-cadherin is
partly attributed to promoter methylation of CDH1  in
IDCs; CDH1 hypermethylation frequency was found to be
50% in IDCs [21]. Taking into account the two major his-
tological subtypes of breast cancer, however, different
modes of E-cadherin expression modulation have been
found. While infiltrating ductal breast cancers mostly
show no or only heterogeneously reduced E-cadherin
expression, infiltrative lobular breast carcinomas (ILC)
are, in most cases (95%), completely E-cadherin-negative
[9-12].
In the present study, we observed loss/or reduced expres-
sion of E-cadherin in 54% (53/98) of IDCs. Similar E-cad-
herin loss was reported in 85% cases in a series of 71
ductal carcinomas and correlated with promoter methyla-
tion of CDH1 [25]. In our previous study in the same
patient cohort, we analyzed the expression patterns of β-
catenin, Disheveled and CyclinD1. Of the 98 IDCs ana-
lyzed, loss of cell surface β-catenin was observed in 66%
cases, whereas nuclear expression was observed in 44%
tumors [20]. In the current study, we found significant
positive association between membranous E-cadherin
and β-catenin loss (p = 0.0001) in IDCs. On this basis, we
postulate that E-cadherin loss promotes tumorigenesis by
effectively releasing membrane bound β-catenin into the
cytosol, there by stimulating the canonical Wnt signaling.
Slug mediated loss of E-cadherin expression in IDCs is
another finding of our study. Although several transcrip-
tion factors including Snail and Slug have been implicated
in E-cadherin repression, herein we have analyzed the
expression of Slug only, because it has been proposed to
be a likely in vivo repressor of E-cadherin as compared to
snail in breast carcinomas [19,37]. Nuclear accumulation
of Slug was observed in 33 of 98 (34%) IDCs, though
lower than reported in a previous study [17], and corre-
lated inversely with tumor grade (p = 0.01) and loss of
membranous E-cadherin expression (p = 0.033) in IDCs.
The association between E-cadherin membrane loss and
its cytoplasmic accumulation with nuclear Slug prompts
us to speculate that Slug may act as a transcriptional sup-
pressor of E-cadherin and regulate its cellular turnover in
IDCs. Furthermore, significant associations between
nuclear and cytoplasmic β-catenin and Slug (p = 0.001; p
= 0.005), underscores the importance of β-catenin medi-
ated regulation of Slug in invasive ductal carcinoma of
breast. In addition, we also performed Immunohisto-
chemistry for E-cadherin and Slug proteins on 5 histolog-
ically confirmed cases of Invasive lobular carcinomas
(Figure 3). Our result is in the agreement with the previ-
ous studies, showing total loss of E-cadherin protein in
ILCs [11,12]. However, we did find nuclear accumulation
of slug in 3 of 5 ILCs. Till date there is no informative
study on Slug protein in ILCs, therefore future studies are
warranted in this specific area for defining/or elucidating
the role of Slug in ILCs.
The other important component of Wnt pathway investi-
gated in our study is GSK3β, a multikinase involved in
Wnt, Akt and Hedgehog pathways, all of which are
involved in determination of cell fate and morphology;
inhibition of GSK3β activity or expression results in bon-
afide EMT [24,38,39]. We observed loss of GSK3β protein
in 53% of IDCs, suggesting endogenous suppression of
Table 2: Analysis of relationships between E-cadherin, Slug and GSK3β expression with β-catenin expression in IDCs.
Parameter Total Cases (N) E-Cad (Mem) E-Cad (Cyto) Slug (Nucl) Gsk3β (Nucl) Gsk3β (Cyto)
-+ P -+ P -+ P -+ P -+ P
98 53 45 46 52 65 33 64 34 52 46
β-catenin (Mem.)
Positive 33 9 24 .0001*1 12 21 .199 16 17 0.012*3 19 14 0.270 19 14 0.669
Negative 65 44 21 34 31 49 16 45 20 33 32
β-catenin (Cyto.)
Positive 42 20 22 0.309 18 24 0.543 21 21 0.005*4 24 18 0.198 17 25 0.070
Negative 56 33 23 28 28 44 12 40 16 35 21
β-catenin (Nucl.)
Positive 47 25 22 1.000 17 30 0.046*2 23 24 0.001*5 28 19 0.292 20 27 0.068
Negative 51 28 23 29 22 42 9 36 15 32 19
Abbreviations: E-cad, E-cadherin; Cyto, Cytoplasmic; Nucl, Nuclear and Mem, Membrane.*1β-cat (Mem)-/E-cad (Mem)-: p = 0.0001; OR = 
5.59 [95% C.I = 2.21-14.1]; *2β-cat (Nucl)+/E-cad (Cyto)+: p = 0.046; OR = 2.33 [95% CI = 1.03-5.25]; *3β-cat (Mem)-/Slug (Nucl)+: p 
= 0.012; OR = 3.25 [95% CI = 1.34-7.89]; *4β-cat (Cyto)+/Slug (Nucl)+: p = 0.005; OR = 3.67 [95% C.I = 1.53-8.83]; *5β-cat (Nucl)+/
Slug (Nucl)+: p = 0.001; OR = 4.87 [95% C.I = 1.94-12.21].BMC Cancer 2009, 9:325 http://www.biomedcentral.com/1471-2407/9/325
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the GSK3β, either due to Wnt or PI3K-kinase, which are
frequently activated in IDCs [20,40]. In the canonical
Wnt/β-catenin pathway, GSK-3β activity in the destruc-
tion complex is inhibited through a yet unclear process,
leading to the accumulation of β-catenin that translocates
to the nucleus and activates transcription by TCF/LEF
transcription factors. In our study, a subset of IDCs (35%)
showed nuclear accumulation of GSK3β protein. Other
plausible reason for nuclear GSK3β accumulation may be
an additional regulation inside the cell and complete inhi-
bition of GSK3β may require activation of multiple sign-
aling pathways simultaneously. Further studies on the
expression profiles of pGSK3β and pAkt, using phospho-
specific antibodies will certainly help in elucidating the
role of GSK3β regulation in Invasive ductal carcinomas of
breast. However, these mechanisms need to be proven in
future studies. We also observed an inverse association of
nuclear GSK3β with tumor grade (p = 0.02), suggesting
that the initial tumor development probably requires a
rapid and effective repression of GSK3β and stabilization
of Slug, thereby inhibiting the expression of E-cadherin.
Interestingly, nuclear GSK3β showed positive association
with ERα expression (p = 0.019), suggesting that GSK3β
may regulate the estrogen receptor mediated transcription
in subsets of IDCs.
In a recent study, we demonstrated the relationship of loss
of E-cadherin and APC proteins with activation of Wnt/β-
catenin signaling driving EMT [21]. We demonstrated
therein, that apart from β-catenin, Disheveled also regu-
lates the expression of Vimentin, establishing direct asso-
ciation of Wnt/β-catenin signaling with EMT. Continuing
our focus on Wnt/β-catenin signaling and EMT, in the
present study we found various relationships among EMT
regulators like β-catenin, E-cadherin and Slug in IDCs
(Table 2).
Expression pattern of E-cadherin, Slug and GSK3β proteins in invasive lobular carcinomas of breast Figure 3
Expression pattern of E-cadherin, Slug and GSK3β proteins in invasive lobular carcinomas of breast. (A& B) 
Invasive lobular carcinomas showing loss of E-cadherin staining (C) Invasive lobular carcinoma showing nuclear staining for Slug 
(D) ILC showing complete loss of GSK3β protein. (A-D, original magnification × 400).
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Our current findings also support the concept that gener-
ation of cancer stem cells (CSCs) - the acquisition of the
stemness and tumorigenic characters is driven by induc-
tion of EMT [41]. In breast cancer, CD44+/CD24- popula-
tion harbors stem cell properties. These CD44+/CD24-
cells, express low or undetectable levels of epithelial
markers (E-cadherin and β-catenin) and high levels of
mesenchymal markers (vimentin and fibronectin), sug-
gesting that these cells have undergone EMT [42]. Expres-
sion of EMT-inducing factors, such as E-cadherin, β-
catenin and Slug, has been shown to be associated with
breast tumor recurrence and metastasis [37,43,44].
Importantly, Wnt signaling has been recently established
to serve as a molecular link between self renewal, EMT,
and metastasis in basal-like breast cancers supporting our
clinical findings [45]. In the presence of Wnt signals, β-
catenin has been proposed to partner with TCF/LEF to
activate target genes, such as Slug and Twist which pro-
mote an EMT, repress differentiation, increase tumor
seeding and metastasis. Thus Wnt signaling effects Slug
and Twist thereby regulating cell-cell adhesion and EMT;
it can also connect EMT with cell fate and differentiation.
Taken together, we speculate that E-cadherin, Slug and
GSK3β could be exploited as markers and pharmacologic
or antibody-based therapies targeting the Wnt pathway
components, which may not only improve the manage-
ment of breast cancer, but also affect tumor recurrence
and/or metastasis.
Conclusion
In the present study, we provide clinical evidence in sup-
port of up-regulation of Wnt/β-catenin signaling in inva-
sive ductal carcinoma of breast and key components of
this signaling pathway such as E-cadherin, Slug, GSK3β
and β-catenin to be associated with Epithelial Mesenchy-
mal Transition (EMT) process and pathogenesis of IDCs.
Moreover, a better understanding of the pathways (such
as the Wnt/β-catenin signaling pathway) that trigger EMT
and cancer cell self renewal (cancer stem cells) might lead
to new therapeutic approaches for cancer patients by
developing molecular tools that interfere with them.
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